Tuesday, July 30, 2013
Category : Non classé | Author : experts

This randomized, double-blind, placebo-controlled study aimed to determine whether follow-up formula supplemented with probiotics (proB) and prebiotics (preB) could reduce the risk of acute otitis media (AOM).
224 children 7 to 13 months old with high risk of AOM received follow-up formula supplemented with proB (Streptococcus thermophilus NCC 2496, Streptococcus salivarius DSM 13084, Lactobacillus rhamnosus LPR CGMCC 1.3724) and preB (Raftilose/Raftiline) or follow-up formula alone (placebo) during 12 months.
Results showed that in total, 486 AOM episodes were reported, 249 and 237 in the treatment and control groups, respectively. The treatment and control groups did not differ in incidence of AOM (IRR 1.0, 95% CI 0.8-1.2), lower respiratory tract infections (IRR 0.9, 0.7-1.2) or number of antibiotic treatment courses (IRR =1.0, (95%CI 0.8-1.2). Treatment was not associated with recurrent AOM (OR 1.0, 95% CI 0.5-1.7). Regarding gastrointestinal disorders, both formulas were well tolerated.
In conclusion, the proB and preB included in follow-up formula given to children at 7 to 13 months of age did not reduce the risk of AOM, recurrent AOM, antibiotic use or lower respiratory tract infections at 1 year.

Pediatr Infect Dis J. 2013 Feb 20
Probiotics and Prebiotics in Preventing Episodes of Acute Otitis Media in High-Risk Children: A Randomized, Double-Blind, Placebo-Controlled Study.
Cohen R, Martin E, de La Rocque F, Thollot F, Pecquet S, Werner A, Boucherat M, Varon E, Bingen E, Levy C.

Leave a Reply